This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suzuki, N. Articles by Shimoyama, T. Search for Related Content PubMed PubMed Citation Articles by Suzuki, N. Articles by Shimoyama, T.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, January 2002, p. 75-78, Vol. 9, No. 1
1071-412X/01/$04.00+0     DOI: 10.1128/CDLI.9.1.75-78.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Production and Application of New Monoclonal Antibodies Specific for a Fecal Helicobacter pylori Antigen

Sagami Research Laboratories, Wakamoto Pharmaceutical Co., Ltd., Ohimachi, Ashigarakami-gun, Kanagawa 258-0018,¹ Department of Infectious Diseases, Tokai University School of Medicine, Isehara, Kanagawa 259-1193,² Department of Internal Medicine 4, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Nishinomiya, Hyogo 663-8501, Japan³

Received 23 April 2001/ Returned for modification 7 August 2001/ Accepted 1 October 2001

	ABSTRACT

Top Abstract Introduction Materials and Methods Results Discussion References

 
The aim of the present study was to establish monoclonal antibodies that could be used to produce a diagnostic test composed of one kind of monoclonal antibody recognizing a fecal Helicobacter pylori antigen. The need to develop such a test arose from disadvantages of the diagnostic test that uses a polyclonal antibody or plural kinds of monoclonal antibodies, such as the lower specificity for H. pylori antigen and the difficulty of reproduction with consistent quality. Mice were immunized with sonicated cells of the coccoid form of H. pylori, and fecal samples from H. pylori-positive subjects were screened by a direct sandwich enzyme immunoassay (EIA) for antibody production from 32 hybridoma clones. The three stable clones produced antibodies (21G2, 41A5, and 82B9) that reacted with the same soluble antigen. Gel filtration chromatography showed that the molecular masses of the cellular antigen and the fecal antigen were the same, 260 kDa. The antigen was labile in response to sodium dodecyl sulfate and heat treatments. A single-step direct sandwich EIA using a single monoclonal antibody, 21G2, was developed. The EIA could detect the antigen in 41 H. pylori clinical isolates and in fecal samples from seven H. pylori-positive subjects. Several kinds of Helicobacter species (Helicobacter felis, Helicobacter hepaticus, Helicobacter mustelae, and Helicobacter cinaedi) except H. pylori, major bacteria in feces (Campylobacter jejuni, Bacteroides vulgatus, Bifidobacterium breve, Bifidobacterium infantis, and Escherichia coli), and fecal samples from six H. pylori-negative subjects showed negative results. These results indicate that the new monoclonal antibodies and the new specific EIA would be useful as a noninvasive method of diagnosis of H. pylori infection.

	INTRODUCTION

Top Abstract Introduction Materials and Methods Results Discussion References

 
Helicobacter pylori causes gastritis and peptic ulcers, and its association with stomach cancer has been studied recently. H. pylori infection can be diagnosed by tests requiring endoscopic biopsy of the gastric mucosa (culture, histology, and the rapid urease test) and by noninvasive tests (serology and the urea breath test) (17). H. pylori is difficult to culture from a fecal sample, because H. pylori outside the stomach probably converts to the nonculturable coccoid form (3, 9).

Recently, enzyme immunoassays (EIAs) for the direct detection of the H. pylori antigens in feces have been developed. These assays include an EIA that uses polyclonal rabbit antibody (Premier Platinum HpSA; Meridian Diagnostics Inc., Cincinnati, Ohio) and an EIA that uses plural kinds of monoclonal antibodies (MAbs) (FemtoLab H. pylori; Connex GmbH, Martinsried, Germany). The EIAs have been shown to be reliable tools for noninvasive diagnosis of H. pylori infection (2, 11, 12, 16). However, the lower specificity of the Premier Platinum HpSA assay has been reported in several articles (5, 6, 15). Moreover, the H. pylori antigen profile in feces that is recognized by the polyclonal antibody or the plural kinds of MAbs remains uncertain and would be of interest to elucidate. Therefore, our interest was to establish MAbs recognizing a fecal H. pylori antigen with a higher specificity so that a more efficient diagnostic test using one kind of MAb could be developed and a more profound study of the H. pylori antigen profile in feces could be performed.

To develop a diagnostic test for H. pylori infection with a higher specificity, we produced new MAbs recognizing the fecal H. pylori antigen and developed a new single-step EIA that used one kind of MAb for the detection of fecal H. pylori antigen.

	MATERIALS AND METHODS

Top Abstract Introduction Materials and Methods Results Discussion References

 
Fecal samples. Fecal samples were obtained from 13 healthy Japanese male subjects (average age, 48 years) and stored at -35°C before use. Seven subjects were H. pylori positive and six subjects were negative for H. pylori by the urea breath test and serology. Consent was obtained from all participants in the study.

Bacterial strains, culture conditions, and preparation of disrupted cells. The following type cultures were used: H. pylori ATCC 43504, H. felis ATCC 49179, H. hepaticus ATCC 51448, H. mustelae ATCC 43772, H. cinaedi ATCC 35683, C. jejuni ATCC 29428, E. coli ATCC 25922, B. vulgatus IFO14291, B. breve JCM1192, and B. infantis JCM1222. Forty-one H. pylori strains isolated from gastric biopsy samples from Japanese patients with gastric ulcer, duodenal ulcer, gastric cancer, gastric mucosa-associated lymphoid tissue lymphoma, or atrophic gastritis were used. Helicobacter species and C. jejuni were cultured on brain heart infusion agar (Difco) plates containing 5% horse blood in a microaerophilic environment (Anaero Pack Helico System; Mitsubishi Gas Chemical Co., Inc.) for 4 days. For transformation of H. pylori to the coccoid form, the culture plates were incubated for a further 7 days in an anaerobic environment (Anaero Pack Anaero System; Mitsubishi Gas Chemical Co., Inc.) (18). B. vulgatus and Bifidobacterium species were cultured anaerobically on glucose blood liver agar (Nissui Pharmaceutical Co., Ltd.) plates containing 5% horse blood for 4 days. E. coli was cultured aerobically on brain heart infusion agar plates for 3 days. All cultures were incubated at 37°C.

Bacterial cells were harvested, washed in phosphate-buffered saline (PBS), suspended in PBS containing 0.5% formalin, and then incubated overnight at 4°C. The bacterial cells were washed three times in PBS and disrupted by sonication (output 3, 50% duty cycle for 10 min) (Biom’c Model 7250; Seiko Instruments & Electronics, Ltd.).

Production of MAbs. The immunogen used to immunize mice consisted of sonicated cells of the coccoid form of H. pylori ATCC 43504. Six BALB/c mice (female, 6weeks old) were immunized by subcutaneous injection of the immunogen mixed with the same volume of Freund’s complete adjuvant (Difco) on day zero. On days 10 and 20, mice were boosted with the immunogen mixed with Freund’s incomplete adjuvant (Difco). On day 27, a final injection of the immunogen without adjuvant was administered intraperitoneally. On day 30, spleen cells and PSX63.Ag8.653 myeloma cells (10:1) were fused with 50% polyethylene glycol (PEG 4000). Hybridoma cells were selected in a hypoxanthine-aminopterin-thymidine medium.

Culture supernatants of hybridoma cells were screened for antibody production by an indirect EIA. Plastic 96-well EIA microtiter plates (Costar) were coated with 200 µl of the immunogen (10 µg of protein/ml in PBS) and incubated overnight at 4°C. After nonspecific binding sites were blocked with 250 µl of PBS containing 1% skim milk (Difco) (blocking buffer) for 1 h at 4°C, 200 µl of each hybridoma clone culture supernatant was added to each well in duplicate. The plates were incubated for 1 h at 37°C, washed five times with PBS containing 0.05% Tween 20 (washing buffer), and further incubated with 200 µl of PBS containing 0.1% skim milk (dilution buffer) and peroxidase-conjugated anti-mouse immunoglobulin G (Cappel; dilution, 1:20,000) for 1 h at 37°C. After five additional washings, 200 µl of substrate solution (8 mM o-phenylenediamine and 3 mM H₂O₂ in 90 mM phosphate buffer [pH 6.0]) was added. The reaction was stopped after 15 min by the addition of 50 µl of 3.5 N H₂SO₄. All assay results were measured with a microplate reader (model 550; Bio-Rad Laboratories) at dual wavelengths (492 and 630 nm).

Screening of MAbs recognizing fecal antigen by direct sandwich EIA. The precipitate containing MAbs was obtained by adding ammonium sulfate to ascitic fluid to a concentration of 50% of its saturation. For labeling, MAbs were biotinylated with biotin-N-hydroxysuccinimide as described in the manufacturer’s instructions (Zymed Laboratories). The fecal samples diluted threefold with dilution buffer were centrifuged at 2,000 x g for 10 min, and the resulting supernatants were used for the EIA. Plastic 96-well EIA microtiter plates were coated with a MAb (5 µg of protein/ml in PBS) and incubated overnight at 4°C. After nonspecific binding sites were blocked as described above, 200 µl of immunogen or fecal supernatant was added to each well in duplicate. The plates were incubated for 1 h at 37°C, washed five times with washing buffer, and incubated with 200 µl of biotinylated MAb (dilution, 1:1,000) for 1 h at 37°C. After five washings, the plates were incubated with 200 µl of peroxidase-conjugated streptavidin (Zymed; dilution, 1:10,000) for 1 h at 37°C. The subsequent peroxidase reaction steps were performed as described above.

Isotyping and isoelectric points of MAbs. MAbs were isotyped with the mouse immunoglobulin typing kit (Wako Pure Chemical Industries, Ltd.). The isoelectric points of the MAbs were determined by isoelectric focusing on a polyacrylamide gel at pH 3 to 10 with a broad pI marker kit (Amersham Pharmacia Biotech).

Characterization of antigen. The sonicated cells of the helical form of H. pylori ATCC 43504 were fractionated by centrifugation. A fecal sample (24 g) from each H. pylori-positive subject was suspended in 100 ml of PBS, and a supernatant was obtained by centrifugation. The molecular weights of cellular and fecal antigens were estimated by Sephacryl S-300 RH (Amersham Pharmacia Biotech) gel filtration column chromatography with molecular weight calibration kits (Amersham Pharmacia Biotech). The antigenicity in each fraction was measured by the direct sandwich EIA method described above. Immunoblotting and dot blotting were performed as described previously (10). Samples were separated by sodium dodecyl sulfate (SDS)-polyacrylamide (4 to 20%) gel electrophoresis and transferred electrophoretically to a nitrocellulose membrane with a semidry transfer cell. For dot blotting, 2 µl of each sample was dotted on a nitrocellulose membrane. The membrane was blocked with 4% (wt/vol) Block Ace (Snow Brand Milk Products Co., Ltd.) at room temperature for 1 h, washed in washing buffer, and incubated in MAb solution (50 µg/ml in Block Ace). The membrane was then washed in washing buffer and incubated with peroxidase-conjugated anti-mouse immunoglobulin G (Cappel; diluted 1:800 in Block Ace) at room temperature for 1 h, and the peroxidase activity was developed in a substrate solution (0.6 mM 3,3'-diaminobenzidine and 4 mM H₂O₂ in PBS).

Direct sandwich EIA using MAb 21G2. MAb 21G2 was purified from ascitic fluid using Affi-Gel protein A (Bio-Rad) column chromatography. For labeling, MAb 21G2 was conjugated with peroxidase by the maleimide method of Ishikawa (8). Microtiter plates were coated with MAb 21G2 and blocked as described above. About 100 mg (0.1 ml) of each fecal sample was diluted in 0.4 ml of dilution buffer. Fifty microliters of diluted fecal sample or sonicated bacterial cells and 50 µl of peroxidase-conjugated MAb 21G2 were added to each well of the plates, and the plates were incubated for 1 h at 25°C. After the plates were washed five times with 250 µl of washing buffer, 100 µl of substrate solution (TMB 1 component microwell peroxidase substrate containing 3,3',5,5'-tetramethylbenzidine and H₂O₂; BioFX Laboratories) was added. The reaction was stopped after 10 min by adding 50 µl of 1 N H₂SO_4, and the absorbance at dual wavelengths (450 nm and 630 nm) was measured on a microplate reader. The cutoff values used were <0.100 for a negative result and 0.100 for a positive result.

Protein determination. Protein concentration was determined with the bicinchoninic acid protein assay reagent (Pierce Chemical Co.) with bovine serum albumin as a standard.

Statistical analysis. The Mann-Whitney U test was used to compare the means of two distributions.

	RESULTS

Top Abstract Introduction Materials and Methods Results Discussion References

 
Screening of MAbs. Thirty-two stable hybridoma clones that reacted with the sonicated H. pylori ATCC 43504 coccoid cells by indirect EIA were obtained. To select MAbs for sensitive sandwich EIA, we screened coating and labeling MAb combinations of 32 clones for reactivity against the immunogen in direct sandwich EIA. Of 1,024 sandwich MAb combinations, 91 could react with the immunogen. Moreover, we tested 91 sandwich MAb combinations for reactivity with fecal samples. As shown in Table 1, in nine sandwich EIAs with three MAbs (21G2, 41A5, and 82B9), the absorbance values of fecal supernatants from four H. pylori-positive subjects were markedly higher than those from three negative subjects.

Characterization of antigen. In two sandwich EIAs using the three MAbs [(i) coating, 21G2; labeling, 41A5; (ii) coating, 41A5; labeling, 82B9], the reactivity of the sonicated H. pylori ATCC 43504 helical forms was similar to that of coccoid forms (data not shown). The result indicated that antigens recognized by the MAbs are conserved during morphological conversion. Thus, we used the helical form of H. pylori ATCC 43504 for antigen characterization. The reactivity of the sonicated H. pylori helical forms was about 100 times higher than that of intact cells in the two sandwich EIAs (data not shown). To locate antigens in H. pylori cells, we measured the antigenicity in the cellular fractions (Fig. 1A). Because the antigenicity per protein was the highest in the soluble fraction, it could be assumed that the antigen was present mainly in the soluble fraction in the cytoplasm, not exposed to the cellular surface. In a fecal sample from an H. pylori-positive subject as well, most of the antigenicity was detected in the ultracentrifugal supernatant (Fig. 1B).

View larger version (11K): [in this window] [in a new window]   FIG. 1. Antigen detection in centrifuged fractions of H. pylori cells and feces. (A) The sonicated cells () (49 mg of protein) of the helical form of H. pylori ATCC 43504 were fractionated into a crude envelope preparation () (18 mg of protein) and a soluble fraction () (6.4 mg of protein) by ultracentrifugation at 90,000 x g for 30 min. (B) A fecal sample (24 g) from an H. pylori-positive subject was suspended in 100 ml of PBS and separated by centrifugation, the supernatant at 2,000 x g for 10 min () (936 mg of protein) and the ultracentrifugal precipitate () (54 mg of protein) and ultracentrifugal supernatant () (712 mg of protein) at 90,000 x g for 30 min. The antigenicity in each sample was measured by direct sandwich EIA (coating MAb, 21G2; labeling MAb, 41A5).

View larger version (18K): [in this window] [in a new window]   FIG. 2. Gel filtration chromatography of the soluble fraction of H. pylori cells and fecal supernatant. Two milliliters of the soluble fraction from H. pylori ATCC 43504 cells () (300 µg of protein per ml) or the ultracentrifugal supernatant of a fecal sample from an H. pylori-positive subject (•) (10 mg of protein per ml) was applied to a Sephacryl S-300 RH column (1.5 by 140 cm), and the column was eluted with buffer (0.1 M phosphate buffer, pH 6.5). The antigenicity in each fraction (2.3 ml) was measured by direct sandwich EIA (coating MAb, 41A5; labeling MAb, 82B9). Marker proteins were thyroglobulin (669 kDa), ferritin (440 kDa), catalase (232 kDa), aldolase (158 kDa), bovine serum albumin (67 kDa), and cytochrome c (12.4 kDa).

Development of single-step direct sandwich EIA with one MAb. For clinical application, we developed a single-step direct sandwich EIA using one kind of MAb. We selected MAb 21G2 because of its stable and high productivity in ascitic fluid. In the EIA, the lower limit for detection of the H. pylori soluble fraction was 37.5 ng of protein/ml and the minimal number of bacteria required for detection was estimated to be 10⁵ per ml. To show the sensitivity and specificity of the EIA, we tested the reactivity of the MAb with 41 H. pylori clinical isolates, different kinds of Helicobacter species (H. felis, H. hepaticus, H. mustelae, and H. cinaedi), and major bacteria in feces (C. jejuni, B. vulgatus, E. coli, B. breve, and B. infantis) (Table 2). The EIA reacted with all H. pylori clinical isolates at 1 µg of protein/ml but did not react with the other kinds of bacterial species at 200 µg of protein/ml. To evaluate the clinical application, we measured 13 fecal samples by the EIA. The mean absorbance values of the fecal samples were 1.56 (range, 0.284 to 3.5; all positive) and 0.032 (range, 0.019 to 0.067; all negative) in seven H. pylori-positive and six H. pylori-negative subjects, respectively (P < 0.01, Mann-Whitney U test).

	DISCUSSION

Top Abstract Introduction Materials and Methods Results Discussion References

The first goal of our screening was to find antibodies that were specific for the coccoid form of H. pylori, because it is well known that H. pylori outside the stomach probably converts from the helical form to the coccoid form. Therefore, we used the H. pylori coccoid form as an immunogen in our first screening. However, the MAbs finally obtained, 21G2, 41A5, and 82B9, were the antibodies that reacted with both the coccoid and the helical forms.

The two direct sandwich EIAs [(i) coating MAb, 21G2; labeling MAb, 41A5; (ii) coating MAb, 41A5; labeling MAb, 82B9] with different combinations of the three MAbs could react with the soluble fraction in the H. pylori cells and with fecal samples (Fig. 1 and 2). Therefore, it was clear that 21G2, 41A5, and 82B9 recognized the same single antigen, although they are different MAbs because of their different isoelectric points. Furthermore, the structure of the antigen in both H. pylori and feces was considered to consist of more than one epitope, like a homodimer, because the sandwich EIA consisting of one kind of coating MAb and a different labeling MAb could detect the antigen. To compare the antigen of H. pylori and that in feces, gel filtration chromatography was performed. The elution patterns of both antigens were almost the same, and the molecular masses of both antigens were estimated to be 260 kDa. Therefore, it was assumed that the fecal antigen recognized by the MAbs was an antigen of H. pylori which was excreted in intact form without being denatured in the gut. Although several papers have reported the production and application of a MAb specific for H. pylori antigen (1, 4, 7, 13, 14), there has been no report on a MAb specific for a distinct fecal H. pylori antigen. To elucidate the H. pylori antigen profile in feces and to guarantee H. pylori diagnosis when the H. pylori antigen in feces is used, identification of the fecal H. pylori antigen is important.

The high sensitivity and specificity of the single-step direct sandwich EIA developed for H. pylori and fecal samples have been elucidated by comparative studies of the assay’s reactivity with some Helicobacter species and with major bacteria in feces. Therefore, the EIA developed in the present study, which is characterized by the application of one kind of MAb, would be useful as a diagnostic tool for H. pylori infectious diseases.

	FOOTNOTES

 
* Corresponding author. Mailing address: Sagami Research Laboratories, Wakamoto Pharmaceutical Co., Ltd., Ohimachi, Ashigarakami-gun, Kanagawa 258-0018, Japan. Phone: 81-465-83-8046. Fax: 81-465-85-1153. E-mail: hirata{at}wakamoto-pharm.co.jp.

	REFERENCES

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Bölin, I., H. Lönroth, and A.-M. Svennerholm. 1995. Identification of Helicobacter pylori by immunological dot blot method based on reaction of a species-specific monoclonal antibody with a surface-exposed protein. J. Clin. Microbiol. 33:381–384.[Abstract]
2. Chang, M. C., M. S. Wu, H. H. Wang, H. P. Wang, and J. T. Lin. 1999. Helicobacter pylori stool antigen (HpSA) test—a simple, accurate and non-invasive test for detection of Helicobacter pylori infection. Hepato-Gastroenterology 46:299–302.[Medline]
3. Dore, M. P., M. S. Osato, H. M. Malaty, and D. Y. Graham. 2000. Characterization of a culture method to recover Helicobacter pylori from the feces of infected patients. Helicobacter 5:165–168.[CrossRef][Medline]
4. Engstrand, L., C. Pahlson, S. Gustavsson, and A. Schwan. 1986. Monoclonal antibodies for rapid identification of Campylobacter pyloridis. Lancet ii:1402–1403.
5. Forné, M., J. Domínguez, F. Fernández-Bañares, J. Lite, M. Esteve, N. Galí, J. C. Espinós, S. Quintana, and J. M. Viver. 2000. Accuracy of an enzyme immunoassay for the detection of Helicobacter pylori in stool specimens in the diagnosis of infection and posttreatment check-up. Am. J. Gastroenterol. 95:2200–2205.[Medline]
6. Guslandi, M. 2000. Stool immunoassay for Helicobacter pylori is not specific enough. BMJ 320:1541.[Free Full Text]
7. Husson, M. O., and H. Leclerc. 1991. Specificity of monoclonal antibodies against Helicobacter pylori. Syst. Appl. Bacteriol. 14:295–298.
8. Ishikawa, E. 1983. Enzyme-labelling of antibodies. J. Immunoassay 4:209–327.[Medline]
9. Kusters, J. G., M. M. Gerrits, J. A. G. Van Strijp, and C. M. J. E. Vandenbroucke-Grauls. 1997. Coccoid forms of Helicobacter pylori are the morphologic manifestation of cell death. Infect. Immun. 65:3672–3679.[Abstract]
10. Lam, J. S., and L. M. Mutharia. 1994. Antigen-antibody reactions, p. 104–132. In P. Gerhardt, R. G. E. Murray, W. A. Wood, and N. R. Krieg (ed.), Methods for general and molecular bacteriology. American Society for Microbiology, Washington, D.C.
11. Makristathis, A., E. Pasching, K. Schütze, M. Wimmer, M. L. Rotter, and A. M. Hirschl. 1998. Detection of Helicobacter pylori in stool specimens by PCR and antigen enzyme immunoassay. J. Clin. Microbiol. 36:2772–2774.[Abstract/Free Full Text]
12. Makristathis, A., W. Barousch, E. Pasching, C. Binder, C. Kuderna, P. Apfalter, M. L. Rotter, and A. M. Hirschl. 2000. Two enzyme immunoassays and PCR for detection of Helicobacter pylori in stool specimens from pediatric patients before and after eradication therapy. J. Clin. Microbiol. 38:3710–3714.[Abstract/Free Full Text]
13. Negrini, R., L. Lisato, L. Cavazzini, P. Maini, S. Gullini, O. Basso, G. Lanza, Jr., M. Garofalo, and I. Nenci. 1989. Monoclonal antibodies for specific immunoperoxidase detection of Campylobacter pylori. Gastroenterology 96:414–420.[Medline]
14. Osaki, T., H. Yamaguchi, H. Taguchi, M. Fukuda, H. Kawakami, H. Hirano, S. Watanabe, A. Takagi, and S. Kamiya. 1998. Establishment and characterization of a monoclonal antibody to inhibit adhesion of Helicobacter pylori to gastric epithelial cells. J. Med. Microbiol. 47:505–512.[Abstract]
15. Trevisani, L., S. Sartori, F. Galvani, M. R. Rossi, M. Ruina, C. Chiamenti, and M. Caselli. 1999. Evaluation of a new enzyme immunoassay for detecting in feces: a prospective pilot study. Am. J. Gastroenterol. 94:1830–1833.[CrossRef][Medline]
16. Vaira, D., P. Malfertheiner, F. Megraud, A. T. Axon, M. Deltenre, A. M. Hirschl, G. Gasbarrini, C. O’Morain, J. M. Garcia, M. Quina, and G. N. Tytgat. 1999. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet 354:30–33.[CrossRef][Medline]
17. Walsh, J. H., and W. L. Peterson. 1995. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N. Engl. J. Med. 333:984–991.[Free Full Text]
18. Yamaguchi, H., T. Osaki, M. Takahashi, H. Taguchi, and S. Kamiya. 1999. Colony formation by Helicobacter pylori after long-term incubation under anaerobic conditions. FEMS Microbiol. Lett. 175:107–111.[CrossRef][Medline]

This article has been cited by other articles:

• Suzuki, N., Wakasugi, M., Nakaya, S., Kokubo, N., Sato, M., Kajiyama, H., Takahashi, R., Hirata, H., Ezure, Y., Fukuda, Y., Shimoyama, T. (2002). Catalase, a Specific Antigen in the Feces of Human Subjects Infected with Helicobacter pylori. CVI 9: 784-788 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suzuki, N. Articles by Shimoyama, T. Search for Related Content PubMed PubMed Citation Articles by Suzuki, N. Articles by Shimoyama, T.